Track ANVS and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
Annovis Bio Inc
101 Lindenwood Drive, Malvern, PA, United States, 19355
IPO
2010
Employees
7
Industry
Biotechnology
Sector
Healthcare
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
Insider Transactions
Quarterly buy vs. sell activity
Sell (left)Buy (right)
Q2 20260+1
1
Q4 20250+6
6
2-quarter cumulative
0 sells7 buys
Analyst Ratings
2 analysts covering
Buy50%recommend buy
Buy
1
Hold
1
Sell
0